| 发明名称 |
TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE |
| 摘要 |
Combined administration of a hypoxia-activated prodrug, such as TH-302, a taxane, such as nab-paclitaxel, and a nucleoside analog chemotherapeutic, such as gemcitabine, are efficacious in the treatment of cancer, including pancreatic cancer. |
| 申请公布号 |
US2016158253(A1) |
申请公布日期 |
2016.06.09 |
| 申请号 |
US201414907190 |
申请日期 |
2014.07.23 |
| 申请人 |
THRESHOLD PHARMACEUTICALS, INC. ;MERCK PATENT GMBH |
发明人 |
HART CHARLES P.;SUN JESSICA D.;ELENBAAS BRIAN A.;GUALBERTO ANTONIO |
| 分类号 |
A61K31/675;A61K31/337;A61K47/48;A61K31/7068 |
主分类号 |
A61K31/675 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A combination of pharmaceutical agents comprising a hypoxia-activated prodrug and a taxane for simultaneous or sequential use in the treatment of pancreatic cancer. |
| 地址 |
South San Francisco CA US |
